The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans

Advanced Drug Delivery Reviews

Volumn 54, Issue 10, 2002, Pages 1295-1310

  Fromm, Martin F ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Blood brain barrier; Digoxin; Drug efflux; Drug transport; HIV; Intestine; Pharmacokinetics; Placenta; SNP

Indexed keywords

BIOLOGICAL MEMBRANES; DISEASES; DRUG PRODUCTS; GENES; TUMORS;

POLYMORPHISMS;

PROTEINS;

ACETYLDIGOXIN; ADENOSINE TRIPHOSPHATE; ALPHA METHYLDIGOXIN; AMPRENAVIR; CARDIAC AGENT; CYCLOSPORIN A; DACTINOMYCIN; DAUNORUBICIN; DIGITOXIN; DIGOXIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; INDINAVIR; IRINOTECAN; MEMBRANE PROTEIN; MITOMYCIN C; MITOXANTRONE; NELFINAVIR; PACLITAXEL; QUINIDINE; RITONAVIR; SAQUINAVIR; TACROLIMUS; TENIPOSIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; XENOBIOTIC AGENT;

BIOAVAILABILITY; DRUG DISPOSITION; GENETIC POLYMORPHISM; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TISSUE DISTRIBUTION; TUMOR CELL CULTURE; ASIAN; BIOSYNTHESIS; CAUCASIAN; ENZYME SPECIFICITY; GENE; GENE FREQUENCY; GENETICS; GENOTYPE; INTESTINE; KIDNEY; LIVER; METABOLISM; NEGRO;

AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENES, MDR; GENOTYPE; HUMANS; INTESTINES; KIDNEY; LIVER; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY;

EID: 0037131893     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00064-9     Document Type: Article

References (87)

1. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
2. Higgins C.F., Gottesman M.M. Is the multidrug transporter a flippase? Trends Biochem. Sci. 17:1992;18-21.
3. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:1999;361-398.
4. Litman T., Druley T.E., Stein W.D., Bates S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci. 58:2001;931-959.
5. Watkins P.B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27:1997;161-170.
6. Benet L.Z., Cummins C.L. The drug efflux-metabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev. 50:(Suppl 1):2001;S3-S11.
7. Ayrton A., Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica. 31:2001;469-497.
8. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.-P., von Richter O., Zundler J., Kroemer H.K. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104:1999;147-153.
9. Fromm M.F., Kim R.B., Stein C.M., Wilkinson G.R., Roden D.M. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation. 99:1999;552-557.
10. Westphal K., Weinbrenner A., Zschiesche M., Franke G., Knoke M., Oertel R., Fritz P., von Richter O., Warzok R., Hachenberg T., Kauffmann H.M., Schrenk D., Terhaag B., Kroemer H.K., Siegmund W. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68:2000;345-355.
11. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84:1987;7735-7738.
12. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A. 86:1989;695-698.
13. Rao V.V., Dahlheimer J.L., Bardgett M.E., Snyder A.Z., Finch R.A., Sartorelli A.C., Piwnica-Worms D. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci. U.S.A. 96:1999;3900-3905.
14. MacFarland A., Abramovich D.R., Ewen S.W., Pearson C.K. Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem. J. 26:1994;417-423.
15. Klimecki W.T., Futscher B.W., Grogan T.M., Dalton W.S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 83:1994;2451-2458.
16. Wacher V.J., Wu C.Y., Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13:1995;129-134.
17. Kim R.B., Wandel C., Leake B., Cvetkovic M., Fromm M.F., Dempsey P.J., Roden M.M., Belas F., Chaudhary A.K., Roden D.M., Wood A.J.J., Wilkinson G.R. Interrelationship between substrates and inhibitors of human CYP3A and P-glykoprotein. Pharm. Res. 16:1999;408-414.
18. Cvetkovic M., Leake B., Fromm M.F., Wilkinson G.R., Kim R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27:1999;866-871.
19. Kullak-Ublick G.A., Ismair M.G., Stieger B., Landmann L., Huber R., Pizzagalli F., Fattinger K., Meier P.J., Hagenbuch B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 120:2001;525-533.
20. Mickley L.A., Lee J.S., Weng Z., Zhan Z., Alvarez M., Wilson W., Bates S.E., Fojo T. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood. 91:1998;1749-1756.
21. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmöller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 97:2000;3473-3478.
22. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., Schäffeler E., Eichelbaum M., Brinkmann U., Roots I. Frequency of single nucleotide polymorphisms (SNPs) in the P-glycoprotein drug transporter MDR1 gene in Caucasians. Clin. Pharmacol. Ther. 69:2001;169-174.
23. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., Taylor A., Xie H.G., McKinsey J., Zhou S., Lan L.B., Schuetz J.D., Schuetz E.G., Wilkinson G.R. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70:2001;189-199.
24. Schaeffeler E., Eichelbaum M., Brinkmann U., Penger A., Asante-Poku S., Zanger U., Schwab M. Application of DHPLC to detect known and novel mutations in the MDR1 gene in different ethnicities. Pharmacol. Toxicol. (Abstract). 89:(Suppl 1):2001;105.
25. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., Takahashi M., Kurata Y., Kigawa J., Higuchi S., Terakawa N., Otsubo K. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297:2001;1137-1143.
26. Nakamura T., Sakaeda T., Horinouchi M., Tamura T., Aoyama N., Shirakawa T., Matsuo M., Kasuga M., Okumura K. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. 71:2002;297-303.
27. + natural killer cells. Pharmacogenetics. 11:2001;1-6.
28. Fellay J., Marzolini C., Meaden E.R., Back D.J., Buclin T., Chave J.-P., Decosterd L.A., Furrer H., Opravil M., Pantaleo G., Retelska D., Ruiz L., Schinkel A.H., Vernazza P., Eap C.B., Telenti A. for the Swiss HIV Cohort Study, Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenentics study. Lancet. 359:2002;30-36.
29. Sakaeda T., Nakamura T., Horinouchi M., Kakumoto M., Ohmoto N., Sakai T., Morita Y., Tamura T., Aoyama N., Hirai M., Kasuga M., Okumura K. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 18:2001;1400-1404.
30. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:1996;2517-2524.
31. Kerb R., Aynacioglu A.S., Brockmöller J., Schlagenhaufer R., Bauer S., Szekeres T., Hamwi A., Fritzer-Szekeres M., Baumgartner C., Öngen H.Z., Güzelbey P., Roots I., Brinkmann U. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics. 1:2001;204-210.
32. Pauli-Magnus C., Feiner J., Brett C., Lin E.T., Kroetz D.L. No effect of MDR1 C3435T polymorphism on disposition and CNS effects of loperamide. Clin. Pharmacol. Ther. (Abstract). 71:2002;P72.
33. Gießmann T., Ludwig K., Franke G., Popowski K., Zschiesche M., Terhaag B., Cascorbi I., Kroemer H.K., Siegmund W. The disposition of talinolol is influenced by the MDR1 genotype in man. Naunyn Schmiedebergs Arch. Pharmacol. (Abstract). 363:(Suppl):2001;R120.
34. Drescher S., Schaeffeler E., Hitzl M., Hofmann U., Schwab M., Brinkmann U., Eichelbaum M., Fromm M.F. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 53:2002;526-534.
35. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:1998;289-294.
36. Alsenz J., Steffen H., Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Coco-2 cell monolayers. Pharm. Res. 15:1998;423-428.
37. Lee C.G., Gottesman M.M., Cardarelli C.O., Ramachandra M., Jeang K.T., Ambudkar S.V., Pastan I., Dey S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 37:1998;3594-3601.
38. Lee C.G., Ramachandra M., Jeang K.T., Martin M.A., Pastan I., Gottesman M.M. Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J. 14:2000;516-522.
39. Choo E.F., Leake B., Wandel C., Imamura H., Wood A.J., Wilkinson G.R., Kim R.B. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 28:2000;655-660.
40. Huang L., Wring S.A., Woolley J.L., Brouwer K.R., Serabjit-Singh C., Polli J.W. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab. Dispos. 29:2001;754-760.
41. Schuetz E.G., Schinkel A.H., Relling M.V., Schuetz J.D. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 93:1996;4001-4005.
42. Lan L.B., Dalton J.T., Schuetz E.G. Mdr1 limits CYP3A metabolism in vivo. Mol. Pharmacol. 58:2000;863-869.
43. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H.L., Turgeon D.K., Schmiedlin R., Brown M.B., Guo W., Rossi S.J., Benet L.Z., Watkins P.B. Role of intestinal P-glycoprotein ( mdr1 ) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62:1997;248-260.
44. von Ahsen N., Richter M., Grupp C., Ringe B., Oellerich M., Armstrong V.W. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. 47:2001;1048-1052.
45. Wandel C., Kim R.B., Wood A.J.J., Stein C.M. 'Inactive' ingredients may alter bioavailability of drugs through effects on P-glycoprotein (PGP) and CYP3A. Clin. Pharmacol. Ther. (Abstract). 69:2001;P71.
46. Stanulla M., Schaeffeler E., Schrappe M., Arens S., Rathmann A., Welte K., Eichelbaum M., Zanger U.M., Schwab M. An association between the MDR1 C3435T polymorphism and CNS relapse in childhood ALL. Eur. J. Clin. Pharmacol. (Abstract). 57:2001;A28.
47. Furuno T., Landi M.T., Ceroni M., Martignoni E., Schaeffeler E., Eichelbaum M., Schwab M., Zanger U. MDR1 polymorphism and Parkinson's disease. Drug Metab. Rev. (Abstract). 33:2001;129.
48. Hermiston M.L., Gordon J.I. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science. 270:1995;1203-1207.
49. Dianda L., Hanby A.M., Wright N.A., Sebesteny A., Hayday A.C., Owen M.J. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am. J. Pathol. 150:1997;91-97.
50. Panwala C.M., Jones J.C., Viney J.L. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J. Immunol. 161:1998;5733-5744.
51. Schaeffeler E., Eichelbaum M., Brinkmann U., Penger A., Asante-Poku S., Zanger U.M., Schwab M. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 358:2001;383-384.
52. Ameyaw M.-M., Regateiro F., Li T., Liu X., Tariq M., Mobarek A., Thornton N., Folayan G.O., Githang'a J., Indalo A., Ofori-Adjei D., Price-Evans D., McLeod H.L. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 11:2001;217-221.
53. Min D.I., Lee M., Ku Y.M., Flanigan M. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin. Pharmacol. Ther. 68:2000;478-486.
54. Mancinelli L.M., Frassetto L., Floren L.C., Dressler D., Carrier S., Bekersky I., Benet L.Z., Christians U. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin. Pharmacol. Ther. 69:2001;24-31.
55. Ito S., Ieiri I., Tanabe M., Suzuki A., Higuchi S., Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2 /cMOAT, in healthy Japanese subjects. Pharmacogenetics. 11:2001;175-184.
56. Dürr D., Stieger B., Kullak-Ublick G.A., Rentsch K.M., Steinert H.C., Meier P.J., Fattinger K. St John's Wort induces intestinal P-glycoprotein/ MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68:2000;598-604.
57. Cordon-Cardo C., O'Brien J.P., Boccia J., Casals D., Bertino J.R., Melamed M.R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38:1990;1277-1287.
58. Lankas G.R., Wise L.D., Cartwright M.E., Pippert T., Umbenhauer D.R. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol. 12:1998;457-463.
59. Jette L., Murphy G.F., Leclerc J.M., Beliveau R. Interaction of drugs with P-glycoprotein in brain capillaries. Biochem. Pharmacol. 50:1995;1701-1709.
60. Wils P., Phung-Ba V., Warnery A., Lechardeur D., Raeissi S., Hidalgo I.J., Scherman D. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem. Pharmacol. 48:1994;1528-1530.
61. Bart J., Groen H.J., Hendrikse N.H., van der Graaf W.T., de Vaalburg V.E. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat. Rev. 26:2000;449-462.
62. Sugiyama Y., Kato Y., Chu X. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother. Pharmacol. 42:(Suppl.):1998;S44-S49.
63. Relling M.V. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther. Drug Monit. 18:1996;350-356.
64. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Beijnen J.H., van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U.S.A. 94:1997;2031-2035.
65. Hoki Y., Fujimori A., Pommier Y. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother. Pharmacol. 40:1997;433-438.
66. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., Van der Valk M.A., Robanus-Maandag E.C., te Riele H.P., Berns A.J.M., Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:1994;491-502.
67. Pauli-Magnus C., Mürdter T., Godel A., Mettang T., Eichelbaum M., Klotz U., Fromm M.F. P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch. Pharmacol. 363:2001;337-343.
68. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A., Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1995;1698-1705.
69. Polli J.W., Jarrett J.L., Studenberg S.D., Humphreys J.E., Dennis S.W., Brouwer K.R., Woolley J.L. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 16:1999;1206-1212.
70. Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268:1993;6077-6080.
71. Schuetz E.G., Yasuda K., Arimori K., Schuetz J.D. Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch. Biochem. Biophys. 350:1998;340-347.
72. Ito T., Yano I., Tanaka K., Inui K.I. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J. Pharmacol. Exp. Ther. 282:1997;955-960.
73. de Lange E., Marchand S., van den Berg D., van der Sandt I., de Boer A., Delon A., Bouquet S., Couet W. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur. J. Pharm. Sci. 12:2000;85-93.
74. Wu X., Whitfield L.R., Stewart B.H. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm. Res. 17:2000;209-215.
75. Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett. 324:1993;99-102.
76. Wandel C., Kim R.B., Guengerich F.P., Wood A.J. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab. Dispos. 28:2000;895-898.
77. Pauli-Magnus C., von Richter O., Burk O., Ziegler A., Mettang T., Eichelbaum M., Fromm M.F. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J. Pharmacol. Exp. Ther. 293:2000;376-382.
78. Matsuzaki J., Yamamoto C., Miyama T., Takanaga H., Matsuo H., Ishizuka H., Kawahara Y., Kuwano M., Naito M., Tsuruo T., Sawada Y. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier. Biopharm. Drug Dispos. 20:1999;85-90.
79. Karlsson J., Kuo S.M., Ziemniak J., Artursson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol. 110:1993;1009-1016.
80. Wetterich U., Spahn-Langguth H., Mutschler E., Terhaag B., Rosch W., Langguth P. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm. Res. 13:1996;514-522.
81. Collett A., Higgs N.B., Sims E., Rowland M., Warhurst G. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J. Pharmacol. Exp. Ther. 288:1999;171-178.
82. Desrayaud S., Guntz P., Scherrmann J.M., Lemaire M. Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci. 61:1997;153-163.
83. Soldner A., Benet L.Z., Mutschler E., Christians U. Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK- MDR1 and caco-2 cell monolayers. Br. J. Pharmacol. 129:2000;1235-1243.
84. Declèves X., Chevillard S., Charpentier C., Vielh P., Laplanche J.L. A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encoding the P-glycoprotein. Hum. Mutat. 15:2000;486.
85. Chen C.J., Clark D., Ueda K., Pastan I., Gottesman M.M., Roninson I.B. Genomic organization of the human multidrug resistance ( MDR1 ) gene and origin of P-glycoproteins. J. Biol. Chem. 265:1990;506-514.
86. Yoon Y., Chun H., Kim E., Shon J., Bae K., Jang I., Shin J. Genetic and environmental factors influencing on the disposition of digoxin: a population pharmacokinetic approach. Clin. Pharmacol. Ther. (Abstract). 71:2002;P73.
87. Shon J., Chun H., Kim K., Kim E., Yoon Y., Jang I., Shin S., Shin J. The PK and PD of fexofenadine in relation to MDR1 genetic polymorphism in Korean healthy subjects. Clin. Pharmacol. Ther. (Abstract). 71:2002;P71.